Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaymaa S Mousa

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 10, 2010
Current status of vascular endothelial growth factor inhibition in age-related macular degenerationShaker A Mousa, Shaymaa S Mousa
Clinical Ophthalmology (Auckland, N.Z.)|March 19, 2013
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degenerationMichael Thomas, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine|December 11, 2012
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicinePeter Avery, Shaymaa S Mousa, Shaker A Mousa
Drug, Healthcare and Patient Safety|June 25, 2011
Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorderChristine Brady, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine|December 11, 2012
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicineChristopher Barone, Shaymaa S Mousa, Shaker A Mousa
Nutrition and Cancer|August 11, 2005
Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane modelSarah S Mousa, Shaymaa S Mousa, Shaker A Mousa
Drugs of the Future|June 29, 2012
High Density Lipoprotein (HDL) Modulation TargetsShaymaa S Mousa, Robert C Block, Shaker A Mousa
Vascular Health and Risk Management|March 18, 2010
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapyYun Lin, Shaymaa S Mousa, Nabil Elshourbagy, et al.
Experimental Dermatology|June 5, 2009
The multiple faces of nicotine and its implications in tissue and wound repairJohn W Martin, Shaymaa S Mousa, Olfat Shaker, et al.
Pharmacogenomics and Personalized Medicine|December 11, 2012
Pharmacogenomics in osteoporosis: Steps toward personalized medicineRobert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 10, 2010
Current status of vascular endothelial growth factor inhibition in age-related macular degenerationShaker A Mousa, Shaymaa S Mousa
Clinical Ophthalmology (Auckland, N.Z.)|March 19, 2013
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degenerationMichael Thomas, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine|December 11, 2012
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicinePeter Avery, Shaymaa S Mousa, Shaker A Mousa
Drug, Healthcare and Patient Safety|June 25, 2011
Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorderChristine Brady, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine|December 11, 2012
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicineChristopher Barone, Shaymaa S Mousa, Shaker A Mousa
Nutrition and Cancer|August 11, 2005
Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane modelSarah S Mousa, Shaymaa S Mousa, Shaker A Mousa
Drugs of the Future|June 29, 2012
High Density Lipoprotein (HDL) Modulation TargetsShaymaa S Mousa, Robert C Block, Shaker A Mousa
Vascular Health and Risk Management|March 18, 2010
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapyYun Lin, Shaymaa S Mousa, Nabil Elshourbagy, et al.
Experimental Dermatology|June 5, 2009
The multiple faces of nicotine and its implications in tissue and wound repairJohn W Martin, Shaymaa S Mousa, Olfat Shaker, et al.
Pharmacogenomics and Personalized Medicine|December 11, 2012
Pharmacogenomics in osteoporosis: Steps toward personalized medicineRobert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al.
Pageof 2